{"id":296021,"date":"2026-04-21T00:00:00","date_gmt":"2026-04-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0005-2024-biopharma-psoriasis-unmet-need-unmet-need-moderate-to-severe-psoriasis-us-eu\/"},"modified":"2026-05-15T23:08:31","modified_gmt":"2026-05-15T23:08:31","slug":"unneim0005-2026-biopharma-psoriasis-unmet-need-unmet-need-moderate-to-severe-psoriasis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0005-2026-biopharma-psoriasis-unmet-need-unmet-need-moderate-to-severe-psoriasis-us-eu\/","title":{"rendered":"Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US\/EU)"},"content":{"rendered":"

Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While conventional systemic agents and TNF<\/abbr>-\u03b1 inhibitors historically dominated early-line therapy, recent years have seen a gradual shift toward earlier use of non-TNF<\/abbr> biologics, particularly IL<\/abbr>-17 inhibitors (e.g., Cosentyx, Taltz, Bimzelx) and IL<\/abbr>-23 inhibitors (e.g., Tremfya, Skyrizi), driven by their superior efficacy and more favorable long-term safety profiles. The market has further expanded with the increased uptake of oral targeted therapies, including PDE4<\/abbr> inhibitor Otezla and, more recently, the oral TYK2<\/abbr> inhibitor Sotyktu, offering non-injectable options for psoriasis patients. Despite the availability of multiple treatments for psoriasis, a substantial unmet need remains. Novel agents are needed that can differentiate on the attributes of efficacy, safety, delivery, and ability to treat a broad patient population.<\/p>\n

QUESTIONS ANSWERED<\/strong><\/p>\n